Hyperkalemia occurred in 17.4% of patients receiving eplerenone alone, compared with 0% for dapagliflozin alone and 4.3% on combined therapy, suggesting that SGLT2 inhibitors may mitigate the potassium elevation typical of MRA therapy [76]. The gene discussed is SLC5A2; the disease is Hyperkalemia.